0
0
Home > Pharmaceuticals >  Central Nervous System >  Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Asessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2021 – 2030

Migraine Drug Market Size, Share & Trends Analysis and Forecast by Strategic Competitor Asessment, Market Characterization, Unmet Needs, Clinical Trial Mapping and Implications 2021 – 2030

Migraine is a complex neurological condition characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

The two clinically and commercially relevant segments considered for the classification of migraine in this report are patients with episodic migraine, who suffer up to 14 migraines per month, and patients with chronic migraine, who suffer 15 or more attacks per month.

For patients that experience four or more migraine attacks per month, physicians look to prescribe a preventive treatment. Preventive treatment is considered an additive to acute therapy and minimizes the risk of medication overuse headaches associated with Nonsteroidal anti-inflammatory drug (NSAID) and triptan treatment.

The migraine market in the 7MM was valued at $4.7B in the 2020 baseline year. GlobalData anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.9%, reaching $12.0B by 2030. The major driver for this growth will be the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs). In addition, the launch of five new pipeline products which will have higher annual costs of therapy (ACOTs) when compared with the cost of the most commonly used migraine treatments, will drive further growth into this market. In order of entry, these products will include Axsome Therapeutics’ AXS-07, Zosano Pharma’s Qtrypta, Biohaven Pharmaceutical’s zavegepant (intranasal), Satsuma Pharmaceuticals’ STS101, and Biohaven Pharmaceutical’s zavegepant (oral).

Key Questions Answered

• What are the key migraine treatments available in 2020?

• When will the late stage pipeline products launch, and how will it affect drug sales and the overall migraine market in the 7MM?

• Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.

Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic migraine and chronic migraine) forecast from 2020 to 2030.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The prevalence of migraine is increasing in line with population growth in the 7MM.

Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients’ comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.

The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.

The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.

The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies Mentioned

AbbVie

Amgen

Axsome Therapeutics

Biohaven Pharmaceuticals

Bristol-Myers Squibb

Currax Pharmaceuticals

Eli Lilly

Endo International

Exeltis Healthcare

GlaxoSmithKline

H.Lundbeck

Impel NeuroPharma

Merck

Novartis

Old API Wind-down

Pfizer

Teva Pharmaceuticals

Satsuma Pharmaceuticals

Sosei Heptares

Zosano Pharma Corp

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Migraine: Executive Summary

1.1 Migraine Therapeutics Market will grow to $12.0B

1.2 Key Players Will Maintain Their Competitive Position

1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs

1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

3.2.1 Premonitory Phase

3.2.2 Aura Phase

3.2.3 Headache Phase

3.2.4 Resolution Phase

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 7MM Forecast Methodology

4.4.1 Sources Used

4.4.2 Forecast Assumptions and Methods

4.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine

4.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency

4.4.5 12-Month Total Prevalent Cases of Migraine by Type

4.4.6 12-Month Diagnosed Prevalent Cases of Migraine

4.5 Epidemiological Forecast for Migraine (2020-2030)

4.5.1 12-Month Total Prevalent Cases of Migraine

4.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine

4.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine

4.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic

4.5.5 12-Month Total Prevalent Cases of Migraine by Type

4.5.6 12-Month Diagnosed Prevalent Cases of Migraine

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.1.1 Episodic Migraine

5.1.2 Chronic Migraine

5.2 Additional KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders

7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication

7.4 Access to Effective and Tolerable Prophylactic Treatments

7.5 Physician Education for Diagnosis

7.6 Raise Awareness of the Disease in the General Population

8 R&D Strategies

8.1 Overview

8.1.1 Gepants for Dual-Acting Acute and Preventive Indications

8.1.2 Preventive Drugs with Long Duration of Action

8.1.3 Improving Efficacy of Marketed Migraine Drugs

8.1.4 Novel MOAs

8.2 Clinical Trials Design

8.2.1 Study Design

8.2.2 Endpoints for Migraine Clinical Trials

8.2.3 Patient Recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Acute Treatment for Migraine

10.2.2 Preventive Treatment for Migraine

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Managing Epidemiologist

13.6.6 Global Director of Therapy Analysis and Epidemiology

13.6.7 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Disease Migraine: Key Metrics in the 7MM

Table 2: Migraine Classification from the ICHD-3

Table 3: Diagnostic Criteria for Migraine with Aura

Table 4: Diagnostic Criteria for Migraine without Aura

Table 5: Risk Factors and Comorbidities for Migraine

Table 6: Treatment Guidelines for Disease Migraine

Table 7: Most Prescribed Drugs for Migraine by Class in the 7MM

Table 8: Migraine Market – Global Drivers and Barriers, 2020–2030

Table 9: Key Events Impacting Sales for Migraine in the US, 2020–2030

Table 10: Migraine Market – Drivers and Barriers in the US, 2020–2030

Table 11: Key Events Impacting Sales for Migraine in the 5EU, 2020–2030

Table 12: Migraine Market – Drivers and Barriers in the 5EU, 2020-2030

Table 13: Key Events Impacting Sales for Migraine in Japan, 2020–2030

Table 14: Migraine Market – Drivers and Barriers in Japan, 2020– 2030

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Migraine in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.

Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.

Figure 5: Pathophysiology of a Migraine

Figure 6: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ≥18 Years, 2020

Figure 7: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine

Figure 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency

Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type

Figure 10: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine

Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020

Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020

Figure 13: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ≥18 Years, 2020

Figure 14: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ≥18 Years, 2020

Figure 15: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ≥18 Years, 2020

Figure 16: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020

Figure 17: Unmet Needs and Opportunities in Migraine

Figure 18: Overview of the Development Pipeline in Migraine

Figure 19: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Migraine in the 7MM During the Forecast Period

Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.

Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.

Figure 22: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 23: Global (7MM) Sales Forecast by Country for Migraine in 2020 and 2030

Figure 24: Global (7MM) Sales Forecast by Drug Class for Migraine in 2020 and 2030

Figure 25: Sales Forecast by Class for Migraine in the US in 2020 and 2030

Figure 26: Sales Forecast by Class for Migraine in the 5EU in 2020 and 2030

Figure 27: Sales Forecast by Class for Migraine in the Japan in 2020 and 2030

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports